Research programme: antibody therapeutics - Duke University/Grid Therapeutics

Drug Profile

Research programme: antibody therapeutics - Duke University/Grid Therapeutics

Alternative Names: GT 103

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University
  • Developer Duke University; Grid Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Complement factor H inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Oct 2017 Grid Therapeutics enters into collaboration with Catalent Pharma Solutions to develop and manufacture GT 103 for treatment of Solid tumours
  • 30 Oct 2017 Grid Therapeutics plans a phase I trial of GT 103 for solid tumours (Late-stage disease) in the first half of 2019
  • 22 Aug 2017 Antibodies related to complement factor H licensed to Grid Therapeutics from Duke University for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top